TLDR
- MiniMed (MMED) opened at $19.05, down 4.8% from its $20 IPO offer price on its Nasdaq debut Friday, March 6.
- The company raised $560 million, selling 28 million shares — below the marketed range of $25–$28 per share.
- MiniMed was valued at $5.35 billion at opening.
- Parent company Medtronic (MDT) retains approximately 90% stake post-IPO.
- The listing came on a rough day for markets, with the VIX hitting a four-month high following a weak jobs report.
Get live prices, charts, and KO Scores from KnockoutStocks.com, the data-driven platform ranking every stock by quality and breakout potential.
MiniMed’s long-awaited Nasdaq debut didn’t exactly land the way its bankers had hoped. The diabetes device maker opened at $19.05 on Friday — 4.8% below its $20 IPO price — valuing the company at $5.35 billion.
MiniMed Group, Inc. Common Stock, MMED
It was a rough day all around. The CBOE Volatility Index spiked to a four-month high, driven by a weak jobs report that hit investor sentiment hard. Not exactly the backdrop you want for a market debut.
The offering raised $560 million from the sale of 28 million shares. That’s well short of what was originally targeted — the marketed range was $25 to $28 per share, meaning MiniMed had to cut its price substantially just to get the deal done.
Some analysts had questioned whether the initial valuation was realistic, and the IPO results suggest those doubts had weight.
A Tough Market for New Listings
The broader IPO market has been under pressure for several weeks. Concerns around AI disruption and geopolitical uncertainty have dampened appetite for new listings, slowing deal flow across the board.
MiniMed’s stumble fits that pattern. Even well-known names are finding it hard to command premium valuations right now.
Medtronic (MDT) spun out the unit to raise capital and separate the diabetes business. After the IPO, Medtronic holds roughly a 90.03% stake in MiniMed — or 88.70% if underwriters exercise their option to purchase up to 4.2 million additional shares within 30 days.
The offering is scheduled to close on March 9, 2026.
MiniMed plans to use the proceeds for general corporate purposes, repayment of intercompany debt to Medtronic, and payments tied to assets transferred during the separation process.
Back to Growth After Regulatory Headwinds
The company had faced regulatory scrutiny in prior years over quality management and cybersecurity issues linked to certain devices. It has since addressed those concerns and returned to growth in recent quarters.
MiniMed competes with Beta Bionics, Dexcom (DXCM), Insulet (PODD), and Tandem Diabetes Care (TNDM) in the diabetes tech space.
Its product lineup includes insulin pumps, continuous glucose monitoring systems, and sensors for both type 1 and type 2 diabetes patients.
Medtronic (MDT) closed lower at $93.01 on Thursday ahead of the spin-off debut.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.
